Equities

ARS Pharmaceuticals Inc

SPRY:NMQ

ARS Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)14.86
  • Today's Change0.81 / 5.77%
  • Shares traded2.13m
  • 1 Year change+124.98%
  • Beta0.8745
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments228274254
Total Receivables, Net------
Total Inventory------
Prepaid expenses3.373.327.45
Other current assets, total------
Total current assets232278261
Property, plant & equipment, net0.820.776.95
Goodwill, net------
Intangibles, net------
Long term investments----65
Note receivable - long term------
Other long term assets0.642.96--
Total assets233281333
LIABILITIES
Accounts payable0.761.662.08
Accrued expenses0.921.7213
Notes payable/short-term debt000
Current portion long-term debt/capital leases--0--
Other current liabilities, total00.28--
Total current liabilities2.395.4415
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total0.043.114.76
Total liabilities2.438.5520
SHAREHOLDERS EQUITY
Common stock0.010.010.00
Additional paid-in capital362349500
Retained earnings (accumulated deficit)(131)(77)(186)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.050.41(0.33)
Total equity231273314
Total liabilities & shareholders' equity233281333
Total common shares outstanding969435
Treasury shares - common primary issue000.03
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.